KW-2478

KW-2478 is an HSP90 inhibitor (IC50 = 3.8 nM) . KW-2478 inhibits the growth and induces apoptosis in chronic myeloid leukemia (CML) cells and liver cancer cells. KW-2478 weakens the BCR/ABL and MAPK signaling pathways, leading to increased p27 and p21 expression and decreased cyclin B1 expression. KW-2478 downregulates STAT3 expression. KW-2478 may be used in research on cancers such as CML and liver cancer[1][2].

Product Specifications

CAS Number

[819812-04-9]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Apoptosis; Bcr-Abl; CDK; HSP; p38 MAPK; STAT

Type

Reference compound

Related Pathways

Apoptosis; Cell Cycle/DNA Damage; JAK/STAT Signaling; MAPK/ERK Pathway; Metabolic Enzyme/Protease; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/KW-2478.html

Purity

99.53

Solubility

DMSO : 200 mg/mL (ultrasonic)

Smiles

O=C(N(CCOC)CCOC)CC1=C(C(C2=CC=C(OCCN3CCOCC3)C(OC)=C2)=O)C(O)=CC(O)=C1CC

Molecular Formula

C30H42N2O9

Molecular Weight

574.66

Precautions

H302, H315, H319, H335

References & Citations

[1]Nakashima T, et al. New molecular and biological mechanism of antitumor activities of KW-2478, a novel nonansamycin heat shock protein 90 inhibitor, in multiple myeloma cells. Clin Cancer Res. 2010 May 15;16 (10) :2792-802.|[2]Zeng D, et al. The HSP90 inhibitor KW-2478 depletes the malignancy of BCR/ABL and overcomes the imatinib-resistance caused by BCR/ABL amplification. Exp Hematol Oncol. 2022 May 27;11 (1) :33.|[3]Chang X, et al. Effect of Hsp90 Inhibitor KW-2478 on HepG2 Cells. Anticancer Agents Med Chem. 2019;19 (18) :2231-2242.